Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
University of Colorado, Denver Identifier:
First received: December 10, 2013
Last updated: December 28, 2016
Last verified: December 2016
HIV infection is complicated by high rates of infections and cancers which are often the cause of death rather than the HIV/AIDS virus itself. Treatment of HIV with antiretroviral medications has decreased the frequency of many complications by over 90%, but bacterial pneumonia remains extremely high. Current vaccines are not very effective in preventing these infections in patients with HIV infection. The investigators are studying the cells (B cells) that make antibodies to fight infection by binding to and killing bacteria. The goal is to understand how HIV impairs the ability of B cells to make antibodies in sufficient quantity and of sufficient quality to protect patients with HIV to learn how to enhance protection against these infections. The investigators also seek to understand the role of the bacteria (specifically Streptococcus pneumoniae) that normally live in the nose and throat in the development of pneumonia and other infections.

Condition Intervention
Pneumococcal Infections
Pneumococcal Vaccines
Biological: PCV-13
Biological: PPSV-23

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Resource links provided by NLM:

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • B and T cell subsets [ Time Frame: Weeks -12, 0, 1, 8, 9, 16 ]
    Activation and subset distribution of B and T cell subsets and cluster of differentiation positive (CD4+) T cells and T follicular helper (TFH) cells on days 0 and 7 after stimulation

  • Total IgG, IgM and IgA [ Time Frame: Weeks -12, 0, 1, 8, 9, 16 ]
    Total immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin A (IgA) produced from culture of peripheral blood mononuclear cells (PBMC) stimulated in triplicate with B cell stimuli on day 7 by enzyme-linked immunosorbent assay (ELISA)

  • Antibody-secreting cells [ Time Frame: Weeks 0, 1, 8, 9 ]
    Total IgG, IgM and IgA antibody-secreting cells (ASC) enumerated by enzyme-linked immunospot (ELISPOT) on day 0 and day 7

  • AID and BCL-6 production [ Time Frame: Weeks -12, 0, 1, 8, 9, 16 ]
    RNA extraction for activation-induced cytidine deaminase (AID) and B cell lymphoma protein 6 (BCL6) expression and mutation from stimulated B cells

Secondary Outcome Measures:
  • S.pneumoniae colonization and nasopharyngeal microbiome [ Time Frame: Weeks -12, 0, 8, 16 ]
    Prevalence of nasopharyngeal S. pneumoniae determined by quantitative polymerase chain reaction(Q-PCR) and 16S ribosomal RNA (rRNA) sequencing, related microbiota (commensal bacteria) and correlation between colonization and levels of pneumococcal capsule-specific IgG

  • S.pneumoniae urine antigen positivity [ Time Frame: Week -12 ]
    S. pneumoniae urine antigen positivity in relation to colonization

Estimated Enrollment: 120
Study Start Date: August 2014
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HIV-seronegative
HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
Biological: PCV-13
Other Name: Prevnar
Experimental: HIV-infected
HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
Biological: PCV-13
Other Name: Prevnar
Biological: PPSV-23
Other Name: Pneumovax


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

For HIV-infected subjects:

  • adults aged 18-55 years
  • >200 CD4+ T-cells/microliter
  • no antiretroviral therapy (at the time of nasal swab/week 0)
  • receiving antiretroviral therapy for >6 weeks (at the time of vaccination/week 12)

For HIV-seronegative controls:

  • adults aged 18-55 years

Exclusion Criteria:

For all subjects:

  • age <18 or >55 years
  • history of prior pneumococcal vaccination
  • immunosuppressive therapy, defined as: prednisone >15mg/day currently or >14 days in the past 3 months, cytotoxic agents, anti-metabolites, cyclosporine, anti-tumor necrosis factor, B cell monoclonal antibodies
  • current or chronic pulmonary infection (bacterial, fungal, mycobacterial), pneumonia, or rhinosinusitis within 2 months
  • chronic lung disease
  • renal insufficiency, defined as serum creatinine >1.6
  • active liver disease, including hepatitis C virus infection
  • history of splenectomy
  • history of antibacterial therapy within 3 months of nasal swab (week 0)
  • current alcohol abuse
  • chronic heart disease
  • diabetes
  • current cigarette smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02012309

Contact: Lindsay K Nicholson, MD 303-399-8020 ext 3557
Contact: Edward N Janoff, MD 303-399-8020 ext 3258

United States, Colorado
University of Colorado-Denver Recruiting
Aurora, Colorado, United States, 80045
Denver Health and Hospitals Recruiting
Denver, Colorado, United States, 80204
Denver VA Medical Center Recruiting
Denver, Colorado, United States, 80220
Sponsors and Collaborators
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Edward N Janoff, MD University of Colorado-Denver, Denver VA Medical Center
  More Information

Responsible Party: University of Colorado, Denver Identifier: NCT02012309     History of Changes
Other Study ID Numbers: 13-2405
R01AI108479 ( US NIH Grant/Contract Award Number )
Study First Received: December 10, 2013
Last Updated: December 28, 2016

Keywords provided by University of Colorado, Denver:
Streptococcus pneumoniae infection
Streptococcus pneumoniae colonization
Pneumococcal vaccines
Nasopharyngeal microbiome

Additional relevant MeSH terms:
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017